BetterLife Pharma, Inc. is an emerging biotechnology company, which focuses on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. The firm owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.